ABCC1 and cancer: Glibenclamide exerts its mechanism of action by inhibiting ABC proteins with dissimilar functions, such as the sulfonylurea receptor–SURx, ABCC8–[13], which is associated with the pore-forming inwardly rectifying K+ channel–Kir6.X– (which together form the KATP channels), the cystic fibrosis transmembrane conductance regulator [14], the ABC1 transporter of immune cells [15], the P-glycoprotein (P-gp) [16] and the multidrug resistance-associated protein (MRP) (ABCC1) of cancer cells [17, 18].